Sp977

PART 2: IATROGENIC GASTROINTESTINAL TRACT INJURY: SOME RECENT CONTENDERS

Date
May 8, 2023
Explore related products in the following collection:

Society: AGA

This symposium aims to highlight the immense (but sometimes underrated) importance of clinico-pathologic correlation for optimal patient management. The gastroenterologist would present clinical evaluation/endoscopic findings and the gastrointestinal (GI) pathologist would present pathologic correlates on three different topics to emphasize that working together and optimal communication between clinician and GI pathologist can improve patient management. The first topic would cover iatrogenic GI tract injury by discussing some relatively recently described drugs causing GI tract changes. Some drugs (such as doxycycline) exhibit relatively characteristic histologic features, while there are others (such as sartans) that can show wide histomorphologic overlap with many other major disease entities. Many patients have significant but non-specific symptoms, and hence high index of suspicion is crucial. An optimal communication can lead to pinpointing of the offending drug as the etiology in these cases. The second topic is getting progressively more important in this era of immunotherapy. The clinician will discuss their perspective and indication for biopsies in patients experiencing immune related adverse events secondary to immunotherapy, and the pathologist would present their assessment of varying histopathologic injury patterns that can show wide overlap with a lot of other etiologies and can be easily misdiagnosed, in the absence of clinical history. In the third topic, we intend to go beyond the commonly recognized patterns of esophagitis (such as reflux disease or eosinophilic esophagitis ) and discuss the clinical and pathologic correlates of some unusual forms of esophagitis, , such as lymphocytic esophagitis, sloughing esophagitis, amongst others.

Presenter

Speaker Image for Peter Stanich
Ohio State University Wexner Medical Center

Tracks

Related Products

Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…